Pharmaceuticals Policy and Law
ISSN: 1389-2827
Volume 13; 4 issues
Institutional subscription (print and online) for 2011: €368 / US$505 (including postage and handling)
Click on the subscribe button for more options, including personal subscription prices.
Status Report: Last issue (volume 12:3-4) online on 19 January 2011
Next issue (volume 13:1) scheduled for June 2011

Aims and Scope
Editorial Board
Submission of Manuscripts
Abstracted in

Download flyer for this journal

Prof. José Luis Valverde
Chair Jean Monnet, EU: 'Europe of the Health'
University of Granada
Faculty of Pharmacy
Campus de la Cartuja sn
Granada 18071
Tel.: +34 958 24 38 98
Fax:+34 958 24 89 08

Advisory Board
Dr. Rodica Badescu, RomaniaMr. Enrique Sánchez de León Pérez, Spain
Dr. J. Lyle Bootman, USAMr. Fernand Sauer, France
Mr. Philippe Brunet, BelgiumProf. Walter Schwerdtfeger, Germany
Mr. Patrick Deboyser, BelgiumDr. Milan Smid, Czech Republic
Ms. P. Ann Hoppe, USAProf. José María Suñé Arbussá, Spain
Ms. Linda Horton, USAMr. Josep Torrent-Farnell, United Kingdom
Prof. Tatsuo Kurokawa, JapanMr. Hannes Wahlroos, Finland
Mr. Alan G. Minsk, USAMs. Elisabethann Wright, Belgium
Prof. Francis B. Palumbo, USA 

Submission of Manuscripts 
See instructions to authors.
Aims and Scope 
The new international review, Pharmaceuticals policy and law, appears with the aim of studying and evaluating the legal status of medicinal products in the European Union, and its implications in other markets such as the USA and Japan, without neglecting the specific problems of developing countries. Pharmaceuticals policy and law intends to participate in the process of world convergence of pharmaceutical legislation helped by a network of academic centers specializing in pharmaceutical law, without omitting a scientific, economic and social approach to medicinal products.

The specificity of medicinal products conditions their legal status. Legislation regulating other goods cannot be applied to them. To begin with, they are the result of scientific and technical innovation. Research policies determine their progress. The pharmaceutical industry is, by nature, multinational. But, next to these global trends, different traditions still remain at a national level. Within the EU, barriers to free trade in medicinal products still remain despite more than thirty years of harmonisation. The social dimension of medicinal products is complex and very significant in the preoccupations of our societies. Patenting is essential but not sufficient. The life-cycle of medicinal products is protected by professional responsibility, required in the general concept of health safety. It is important to remember their ethical dimension, including research and innovation in new fields such as genetic manipulation and biotechnology, which requires social consent to preserve human dignity and fundamental rights.
Abstracted in
EBSCO database

IOS Press
Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands
Tel.: +31 20 688 3355, Fax: +31 20 687 0019